Dr. Jan B. Krauß
Partner - Patent Attorney
Pharma & Life Science
Patent attorney
European Patent and Trademark Attorney
Representative before the Unified Patent Court (UPC)
Diplom-Biologe
Focus on expertise
Molecular biology
Immunology
Plant genetics
Pharmaceuticals
Cosmetics
Nutrition
Veterinary medicine
Dr. Jan Krauß specializes in the fields of pharmaceuticals and life sciences - in particular molecular biology, immunology, plant genetics, pharmaceuticals, cosmetics, nutrition and veterinary medicine. For more than 25 years, he has successfully represented both German as well as international clients, in particular innovative companies in the life sciences and pharmaceutical sectors, as well as research institutions and universities in all areas of intellectual property law.
His particular focus is on strategic IP planning, the generation of IP portfolios and the enforcement of IP rights as well as on opposition and nullity proceedings.
Dr. Krauß studied biology at the Free University of Berlin and obtained his doctorate at the Max Planck Institute for Molecular Genetics in Berlin on the genetic basis of antibiotic resistance in pathogenic bacteria. After completing his patent attorney training in Berlin and Munich, he worked in the biotech group of a large US patent law firm in Frankfurt am Main, Germany. Before co-founding SKM-IP he wasa leading partner in a large patent firm in Munich, germany for over 20 years.
Since 2008, he has been an Affiliate Instructor of Law and guest lecturer at the University of Washington, School of Law, Seattle, WA, USA. Since 2016, he regularly teaches at the Paris Lodron University in Salzburg, Austria and regularly conducts seminars on patent claim drafting and freedom-to-operate analysis for the reknown FORUM Institute. He is the author of numerous scientific and patent law articles in both German and international journals.
Dr. Krauß is the CEO of the iotech-startup company KBHB GmbH in Salzburg, Austria.
Dr.Krauß can regularly be found in professional rankings with his technical focus on pharmaceuticals.
Biography
Publications
Wimmer, B., et al. (2023). En Route to Targeted Ribosome Editing to Replenish Skin Anchor Protein LAMB3 in Junctional Epidermolysis Bullosa. JID Innovations. 4. 100240. 10.1016/j.xjidi.2023.100240.
Jan Krauß - News from biotechnology - The "plausibility" at the European Patent Office and the decision G 2/21 Mitteilungen der deutschen Patentanwälte 5/2023, p. 114ff)
Rathner A, et al. Drug Development for Target Ribosomal Protein rpL35/uL29 for Repair of LAMB3R635X in Rare Skin Disease Epidermolysis Bullosa. Skin Pharmacol Physiol.2021;34(4): 167-182. doi: 10.1159/000513260. Epub 2021 Apr 6. PMID: 33823521
Krauß J., Kuttenkeuler D. When to file for a patent? The scientist's perspective. NBiotechnol. 2021 Jan 25;60:124-129. doi: 10.1016/j.nbt.2020.10.006. Epub 2020Oct 19. PMID: 33091617.
Chapter 6: Patenting inventions in medical sciences; in: Takenaka et al, Research Handbook on Patent Lawand Theory 2nd edition 2019 ISBN: 9781 78536 411 2
Jan Krauß - Supplementary protection certificates for combination drugs "Combine: No clarity in sight!" Notices from German Patent Attorneys (2/2019, p. 52ff)
Krauss, Jan & Kuttenkeuler, David. (2017).Intellectual property rights derived from academic research and their role in the modern bioeconomy - A guide for scientists. New Biotechnology. 40.10.1016/j.nbt.2017.06.013.
Toshiko Takenaka, Christoph Rademacher, Jan Krauss, et al. Patent Enforcement in the US, Germany and Japan Oxford University Press; Illustrated edition (17 Feb. 2016) ISBN 978-0-19-967920-1
Memberships
- Chamber of Patent Attorneys, EPI
- Licensing Executive Society International (LESI)
- UNION-IP
- VPP, GRUR
Awards